The German biotech company Curevac is giving up its first-generation Covid-19 vaccine. Together with GSK, it now wants to concentrate on the development of second-generation vaccines.

The Tübingen-based company Curevac is not only working on vaccines, but also, together with a partner, on an “RNA printer” for their production.


The Tübingen-based biopharma company Curevac is withdrawing its first-generation Covid-19 vaccine candidate from the ongoing regulatory review. Instead, they will focus on accelerated development of a second-generation vaccine program together with the British pharmaceutical company GlaxoSmithKline (GSK), Curevac announced on Tuesday.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.